Cancer Treatment Centers Grapple with Ongoing Drug Shortages, Survey Reveals

America's cancer treatment facilities are currently experiencing significant shortages of vital medications, according to a new survey encompassing over 30 academic centers. The findings highlight the troubling reality that nearly all participants reported lacking at least one essential anti-cancer drug, with more than 20% facing shortages of five or more different therapies.

The drugs affected are crucial in treating some of the deadliest cancers, such as testicular, bladder, uterine, ovarian, lung, and breast cancers. The American Cancer Society anticipates that more than 626,000 people in the U.S. will succumb to cancer this year, underscoring the urgency of addressing these shortages.

Severity of Shortages

Among the most impacted drugs are multi-use ifosfamide, which 94% of centers reported shortages of, followed by carboplatin at 71% and cisplatin at 16%. The immunotherapy Bacillus Calmette-Guérin, used for bladder cancer, is also in limited supply at over half of the surveyed centers. This ongoing crisis has forced facilities to implement mitigation strategies to maintain patient care, which diverts resources and adds stress to healthcare providers.

Impact on Patient Care

Dr. Crystal Denlinger, CEO of the National Comprehensive Cancer Network, expressed frustration at the persistence of these shortages, stating, "It is disheartening that we remain in the same situation, including recurring or continued shortages of some drugs, despite years of raising the alarm." The survey revealed that 90% of centers face additional delays due to the necessity of obtaining multiple authorizations from health insurance companies, complicating the treatment process for patients.

Potential Solutions and Legislative Efforts

In response to the crisis, the non-profit organization has proposed several solutions, such as reforming federal drug production policies to stabilize supply chains and incentivizing domestic manufacturing of medications. New cancer vaccines may also offer a pathway to not only mitigate shortages but to personalize treatment options for patients. While legislative measures to confront these issues have been introduced, they have yet to be enacted. The Trump administration indicated efforts to alleviate shortages, including the possibility of temporarily allowing imports from foreign manufacturers.

Source: www.independent.co.uk